Search | Clinical Trials Finder

Conditions: HIV Infections, HIV Seronegativity
Interventions: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: Shigella
Interventions: ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU; Biological · Other
Lead sponsor: Eveliqure Biotechnologies GmbH; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Papillomavirus Vaccines
Interventions: Community Pharmacists Vaccinating Against Cancer; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Sexually Transmitted Diseases
Interventions: NgG 12.5 µg investigational vaccine, NgG 25 µg investigational vaccine, NgG 50 µg investigational vaccine, Placebo; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 1,009 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Lenexa, Kansas • Boston, Massachusetts + 4 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF); Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 60 Years to 99 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Rockville, Maryland

Conditions: Vaccine Hesitancy
Interventions: MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE); Other
Lead sponsor: Cedarville University; Other
Eligibility: 0 Years to 6 Years
Enrollment: 4,191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Springfield, Ohio

Conditions: Atopic Dermatitis
Interventions: Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years to 43 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: San Diego, California • Denver, Colorado • Portland, Oregon

Conditions: Malaria
Interventions: P. falciparum infection, Chloroquine, Primaquine; Biological · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Stress
Interventions: R-CBSM, Influenza vaccine; Behavioral · Biological
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions: Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo; Biological · Drug
Lead sponsor: Serum Life Science Europe GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Seasonal Influenza
Interventions: mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Coral Gables, Florida • Jupiter, Florida + 12 more

Conditions: Cancer
Interventions: Personalized Synthetic Long Peptide Vaccine; Biological
Lead sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines; Other
Eligibility: 12 Years and older
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
Interventions: Cancer vaccine plus immune adjuvant; Biological
Lead sponsor: TVAX Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Vaccination
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 11 Years to 12 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pneumococcal Disease
Interventions: 20vPnC, 13vPnC; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 21
States / cities: Anaheim, California • Sacramento, California • San Jose, California + 16 more

Conditions: COVID-19
Interventions: OCU500; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Decatur, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Melanoma (Skin)
Interventions: BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide; Biological · Drug
Lead sponsor: AVAX Technologies; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 17
States / cities: Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more

Conditions: COVID-19
Interventions: Vaccine Messaging, Vaccine Acceptance Question; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 919 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 7
States / cities: San Francisco, California • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Lung Cancer
Interventions: autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy, biological therapy, conventional surgery, surgery, tumor cell derivative vaccine, vaccine therapy; Drug · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia
Interventions: PR1 leukemia peptide vaccine, sargramostim, placebo; Biological · Other
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Glendale, Arizona • San Diego, California • Vista, California + 3 more

Conditions: Toxic Shock Syndrome Staphylococcal
Interventions: Aluminum hydroxide, STEBVax vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions: Galinpepimut-S, GM-CSF, Montanide; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Community Pharmacists Vaccinate Against Cancer

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Motivational Interviewing and Vaccine Hesitancy in Children

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

Malaria Challenge in Healthy Volunteers

VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

Sleep and Adolescent Vaccine Immunogenicity Pilot/Observational Study

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Phase I STEBVax in Healthy Adults

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)